P374 Safety and drug survival of methotrexate versus tioguanine after failure of conventional thiopurines in patients with Crohn’s disease

Edo Savelkoul(Radboud University Nijmegen), Frank Hoentjen(Radboud University Nijmegen), Femke Crouwel(Amsterdam University Medical Centers), Arno R. Bourgonje(University Medical Center Groningen), M. Maas(University Medical Center Groningen), Gerard Dijkstra(University Medical Center Groningen), Nanne K.H. de Boer, Tessa E H Römkens(Jeroen Bosch Ziekenhuis), M. Russel(Medisch Spectrum Twente)
Journal of Crohn s and Colitis
May 1, 2021
10.1093/ecco-jcc/jjab076.498
Cited by 0

Related Papers

Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease
|Gut|2016|800
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
Complex host genetics influence the microbiome in inflammatory bowel disease
|Genome Medicine|2014|431
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
|The Lancet|2022|301
Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis
|New England Journal of Medicine|2021|269